| abstract |
The subject invention provides a modified release solid oral dosage form comprising a therapeutically effective amount of pridopidine or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable rate controlling excipient, wherein Thus, the solid oral dosage form provides an in vivo plasma pridopidine concentration profile having an average C max of about 1,400 ng / ml or less. The subject invention also provides a method of treating an individual suffering from a neurodegenerative disease or a disease related to dopamine, comprising once daily administration of a controlled release solid oral dosage form. |